舒巴坦与阿维巴坦、杜氯巴坦对耐碳青霉烯鲍曼不动杆菌的体外活性比较。

IF 3.3 Q2 INFECTIOUS DISEASES
JAC-Antimicrobial Resistance Pub Date : 2025-06-23 eCollection Date: 2025-06-01 DOI:10.1093/jacamr/dlaf098
Ava J Dorazio, Ellen G Kline, Kevin M Squires, Marissa P Griffith, Yohei Doi, Ryan K Shields
{"title":"舒巴坦与阿维巴坦、杜氯巴坦对耐碳青霉烯鲍曼不动杆菌的体外活性比较。","authors":"Ava J Dorazio, Ellen G Kline, Kevin M Squires, Marissa P Griffith, Yohei Doi, Ryan K Shields","doi":"10.1093/jacamr/dlaf098","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the <i>in vitro</i> activity of sulbactam in combination with avibactam or durlobactam with and without meropenem or imipenem against carbapenem-resistant <i>Acinetobacter baumannii</i> clinical isolates.</p><p><strong>Methods: </strong>Standardized susceptibility testing by broth microdilution was performed to determine MICs for imipenem, meropenem and sulbactam alone, and for combinations including sulbactam/avibactam, sulbactam/durlobactam, sulbactam/avibactam/meropenem, sulbactam/avibactam/imipenem, sulbactam/durlobactacm/meropenem and sulbactam/durlobactam/imipenem. Whole-genome sequencing was also performed to compare MICs to key resistance determinants, including mutations in penicillin-binding proteins (PBPs).</p><p><strong>Results: </strong>Median sulbactam/durlobactam and sulbactam/avibactam MICs were 2 and 16 mg/L, respectively. Imipenem potentiated the <i>in vitro</i> activity of both combinations to a greater extent than meropenem corresponding to median sulbactam/durlobactam/imipenem and sulbactam/avibactam/imipenem MICs of 1 and 8 mg/L, respectively. Carbapenem combinations were more active than combinations without a carbapenem against isolates with PBP3 mutations.</p><p><strong>Conclusions: </strong>These data show that imipenem potentiates sulbactam-based combinations to a greater extent than meropenem; however, future studies are needed to define how these data should be applied in clinical practice.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf098"},"PeriodicalIF":3.3000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205954/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative <i>in vitro</i> activity of sulbactam with avibactam or durlobactam against carbapenem-resistant <i>Acinetobacter baumannii</i>.\",\"authors\":\"Ava J Dorazio, Ellen G Kline, Kevin M Squires, Marissa P Griffith, Yohei Doi, Ryan K Shields\",\"doi\":\"10.1093/jacamr/dlaf098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To determine the <i>in vitro</i> activity of sulbactam in combination with avibactam or durlobactam with and without meropenem or imipenem against carbapenem-resistant <i>Acinetobacter baumannii</i> clinical isolates.</p><p><strong>Methods: </strong>Standardized susceptibility testing by broth microdilution was performed to determine MICs for imipenem, meropenem and sulbactam alone, and for combinations including sulbactam/avibactam, sulbactam/durlobactam, sulbactam/avibactam/meropenem, sulbactam/avibactam/imipenem, sulbactam/durlobactacm/meropenem and sulbactam/durlobactam/imipenem. Whole-genome sequencing was also performed to compare MICs to key resistance determinants, including mutations in penicillin-binding proteins (PBPs).</p><p><strong>Results: </strong>Median sulbactam/durlobactam and sulbactam/avibactam MICs were 2 and 16 mg/L, respectively. Imipenem potentiated the <i>in vitro</i> activity of both combinations to a greater extent than meropenem corresponding to median sulbactam/durlobactam/imipenem and sulbactam/avibactam/imipenem MICs of 1 and 8 mg/L, respectively. Carbapenem combinations were more active than combinations without a carbapenem against isolates with PBP3 mutations.</p><p><strong>Conclusions: </strong>These data show that imipenem potentiates sulbactam-based combinations to a greater extent than meropenem; however, future studies are needed to define how these data should be applied in clinical practice.</p>\",\"PeriodicalId\":14594,\"journal\":{\"name\":\"JAC-Antimicrobial Resistance\",\"volume\":\"7 3\",\"pages\":\"dlaf098\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-06-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205954/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAC-Antimicrobial Resistance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jacamr/dlaf098\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlaf098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

目的:测定舒巴坦与阿维巴坦或杜氯巴坦联用美罗培南或亚胺培南对耐碳青霉烯鲍曼不动杆菌临床分离株的体外活性。方法:采用微量肉汤稀释法进行亚胺培南、美罗培南、舒巴坦单用、舒巴坦/阿维巴坦、舒巴坦/杜罗巴坦、舒巴坦/阿维巴坦/美罗培南、舒巴坦/阿维巴坦/亚胺培南、舒巴坦/杜罗巴坦/美罗培南、舒巴坦/杜罗巴坦/亚胺培南的标准化药敏试验。还进行了全基因组测序,以比较mic与关键耐药决定因素,包括青霉素结合蛋白(PBPs)的突变。结果:舒巴坦/杜氯巴坦和舒巴坦/阿维巴坦的mic中位数分别为2和16 mg/L。当舒巴坦/杜氯巴坦/亚胺培南和舒巴坦/阿维巴坦/亚胺培南的中位mic分别为1和8 mg/L时,亚胺培南比美罗培南更能增强这两种组合的体外活性。碳青霉烯联用比不加碳青霉烯联用对PBP3突变的分离株更有活性。结论:这些数据表明亚胺培南比美罗培南更能增强以舒巴坦为基础的联合用药;然而,需要进一步的研究来确定这些数据如何应用于临床实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparative in vitro activity of sulbactam with avibactam or durlobactam against carbapenem-resistant Acinetobacter baumannii.

Objective: To determine the in vitro activity of sulbactam in combination with avibactam or durlobactam with and without meropenem or imipenem against carbapenem-resistant Acinetobacter baumannii clinical isolates.

Methods: Standardized susceptibility testing by broth microdilution was performed to determine MICs for imipenem, meropenem and sulbactam alone, and for combinations including sulbactam/avibactam, sulbactam/durlobactam, sulbactam/avibactam/meropenem, sulbactam/avibactam/imipenem, sulbactam/durlobactacm/meropenem and sulbactam/durlobactam/imipenem. Whole-genome sequencing was also performed to compare MICs to key resistance determinants, including mutations in penicillin-binding proteins (PBPs).

Results: Median sulbactam/durlobactam and sulbactam/avibactam MICs were 2 and 16 mg/L, respectively. Imipenem potentiated the in vitro activity of both combinations to a greater extent than meropenem corresponding to median sulbactam/durlobactam/imipenem and sulbactam/avibactam/imipenem MICs of 1 and 8 mg/L, respectively. Carbapenem combinations were more active than combinations without a carbapenem against isolates with PBP3 mutations.

Conclusions: These data show that imipenem potentiates sulbactam-based combinations to a greater extent than meropenem; however, future studies are needed to define how these data should be applied in clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信